diabetes

Brain’s role in diabetes: new approach to insulin regulation
Brain’s role in diabetes: new approach to insulin regulation
GoinPharma
brain
diabetes
insulin
Flag link:
Valeritas touts new data for insulin delivery device
Valeritas touts new data for insulin delivery device
Drug Delivery Business News
Valeritas
V-Go
diabetes
insulin delivery
Flag link:
This tiny chip uses A.I. to control blood sugar levels for critical diabetes patients
This tiny chip uses A.I. to control blood sugar levels for critical diabetes patients
CNBC
diabetes
Admetsys
artificial intelligence
Flag link:
Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback
Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback
Endpoints
teplizumab
Eli Lilly
Provention Bio
IPOs
diabetes
Flag link:
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
Flag link:
Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
Fierce Pharma
diabetes
patients
Novo Nordisk
drug discounts
outcomes-based pricing
Flag link:
AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval
AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval
Drug Delivery Business News
AstraZeneca
diabetes
Bydureon
FDA
Flag link:
10 Events that Rattled Medtech in 1Q18
10 Events that Rattled Medtech in 1Q18
Medical Devices and Diagnostics Industry
devices
InMode
Votiva
JNJ
diabetes
LifeScan
Orthotaxy
robotic surgery
Abbott Labs
HeartMate 3
Medtronic
Guardian Sensor 3
Edwards Lifesciences
Centera valve
SFC Fluidics
EOFlow Co
type 1 diabetes
Boston Scientific
FDA
duodenoscope
PENTAX
Fujifilm
Olympus
Theranos
Elizabeth Holmes
Flag link:
Sanofi seeks to restore leadership in diabetes treatments
Sanofi seeks to restore leadership in diabetes treatments
GoinPharma
Sanofi
diabetes
sotagliflozin
Flag link:
Half-off sale at Eli Lilly as drug rebating climbs to 51% in 2017
Half-off sale at Eli Lilly as drug rebating climbs to 51% in 2017
Fierce Pharma
Eli Lilly
drug rebates
drug pricing
diabetes
Flag link:
FDA committee backs Senseonics’ implantable continuous glucose monitor
FDA committee backs Senseonics’ implantable continuous glucose monitor
Drug Delivery Business News
FDA
Senseonics
devices
diabetes
implantable continuous glucose monitoring
blood glucose monitoring
Eversense
Flag link:
Sanofi’s high-capacity insulin pen wins FDA nod
Sanofi’s high-capacity insulin pen wins FDA nod
Drug Delivery Business News
Sanofi
insulin
insulin pen
FDA
devices
Toujeo
diabetes
Flag link:
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
Drug Delivery Business News
FDA
Novo Nordisk
diabetes
Tresiba
labeling
insulin degludec
Flag link:
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
AstraZeneca touts a fresh cut of Farxiga data targeting diabetes patients with chronic kidney disease
AstraZeneca touts a fresh cut of Farxiga data targeting diabetes patients with chronic kidney disease
Endpoints
AstraZeneca
Farxiga
diabetes
chronic kidney disease
Flag link:
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
Yahoo/Zacks.com
devices
Orthopedics
Stryker
Orthofix
JNJ
robotic surgery
diabetes
regulatory
Flag link:
J&J says offered $2.1 billion for LifeScan diabetes unit
J&J says offered $2.1 billion for LifeScan diabetes unit
Yahoo/Reuters
JNJ
devices
diabetes
M&A
LifeScan
Flag link:
ACC: Waiting on the FDA's heart-helping verdict, J&J touts more positive CV data for Invokana
ACC: Waiting on the FDA's heart-helping verdict, J&J touts more positive CV data for Invokana
Fierce Pharma
ACC
FDA
Invokana
diabetes
Flag link:
Five Events That Disrupted the Diabetes Market
Five Events That Disrupted the Diabetes Market
Medical Devices and Diagnostics Industry
diabetes
devices
DexCom
blood glucose monitoring
Google
Verily
JNJ
Medtronic
MiniMed 670G
artificial pancreas
Abbott Labs
FDA
FreeStyle Libre Flash
Flag link:
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Flag link:

Pages